XML 18 R5.htm IDEA: XBRL DOCUMENT v3.7.0.1
Condensed Consolidated Statements of Cash Flows - USD ($)
 3 Months Ended 6 Months Ended 13 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Cash flows from operating activities:          
Net loss $ (9,479,116) $ (18,704,711) $ (32,565,023) $ (26,747,531)  
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation     1,020,679 827,327  
Amortization of intangible assets 404,000 347,000 810,539 556,554  
Change in value of common stock warrants     196,023 520,025  
Stock-based compensation     7,937,473 5,251,166  
Amortization of premiums on investments     140,599 139,659  
Loss on short-term investments     67,366 0  
Deferred rent     1,869,341 (31,783)  
Loss (gain) on investment in affiliated entity (169,096) 705,527 1,439,721 (6,775,450)  
Gain on sale of intangible assets     0 (1,000,000)  
Changes in operating assets and liabilities:          
Accounts receivable     8,298,963 (3,032,891)  
Accounts receivable from affiliated entity     (440,945) 0  
Prepaid expenses and other current assets     (3,165,705) (270,785)  
Prepaid expenses and other current assets from affiliated entity     260,694 (1,271,605)  
Other assets     438,896 (655,334)  
Accounts payable and accrued expenses     (4,305,114) (247,009)  
Accrued clinical trial expenses     820,362 2,405,804  
Accounts payable and accrued expenses due to affiliated entity     (225,158) 435,922  
Deferred revenue     (14,325,900) 1,323,827  
Deferred revenue from affiliated entity     (219,792) (437,827)  
Net cash used in operating activities     (31,946,981) (29,009,931)  
Cash flows from investing activities:          
Purchases of investments     (14,600,112) (27,985,410)  
Maturities of investments     32,173,342 27,662,695  
Purchases of capital assets     (5,828,137) (2,196,896)  
Proceeds from sale of intangible assets     0 1,000,000  
Purchase of intangible assets and other assets     0 (1,200,000)  
Net cash provided by (used in) investing activities     11,745,093 (2,719,611)  
Cash flows from financing activities:          
Proceeds from issuance of common stock, net of issuance costs     24,060,196 1,301,435 $ 30,400,000
Proceeds from stock option and warrant exercises, net of tax payments     865,857 1,395,346  
Expenses from other financing activities     0 (149,559)  
Net cash provided by financing activities     24,926,053 2,547,222  
Increase (decrease) in cash and cash equivalents     4,724,165 (29,182,320)  
Cash and cash equivalents, beginning of period     19,136,472 57,632,693  
Cash and cash equivalents, end of period 23,860,637 28,450,373 23,860,637 28,450,373 23,860,637
Supplemental disclosure of non-cash activities          
Common stock issued for purchase of intangible and other assets of Bioject     0 4,300,000  
Change in amounts accrued for purchases of property and equipment     1,185,087 (110,136)  
Lease incentive recorded as fixed assets and deferred rent $ 0 $ 134,500 $ 0 $ 134,500 $ 0